Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider
of critical reagents for the development and production of
biopharmaceutical products including drug therapies, novel
vaccines, and molecular diagnostics, today announced financial
results for the second quarter ended June 30, 2021.
“We are pleased with our performance during the second quarter
of 2021, as we continued to see strong demand across our Lab
Essentials and Clinical Solutions product categories,” said Stephen
Gunstream, President and CEO of Teknova. “Together with the
successful completion of our initial public offering, our growing
revenue supports our long-term strategy by fueling investments to
increase production capacity and to extend our commercial and
R&D capabilities in the near term.”
Corporate and Financial Updates
- Second quarter 2021 revenue of $8.3 million, up 38% as compared
to $6.0 million in the second quarter of 2020 and up 41% as
compared to $5.9 million in the second quarter of 2020, when Sample
Transport medium revenue is excluded
- Completed initial public offering, raising approximately $99.1
million in proceeds, after deducting underwriting discounts and
commissions, and other offering expenses
- Strengthened Board with the independent Director appointments
of life science veterans Robert McNamara, Brett Robertson, and
Alexander Vos
- Began construction on new state-of-the art GMP manufacturing
facility in Hollister, CA
- Established our Scientific Affairs team to engage with
scientists active in cell and gene therapy research and
development
Revenue for the Second Quarter and
Year-to-Date
$000s |
Three months ended June 30 |
Six months ended June 30 |
Unaudited |
2021 |
2020 |
YoY Chg |
|
2021 |
2020 |
YoY Chg |
|
|
|
|
|
|
|
|
Lab Essentials |
6,456 |
4,430 |
46 |
% |
13,246 |
9,679 |
37 |
% |
Clinical Solutions |
1,593 |
1,208 |
32 |
% |
2,664 |
1,787 |
49 |
% |
Sample Transport |
37 |
174 |
(78 |
%) |
961 |
174 |
453 |
% |
Other |
227 |
232 |
(2 |
%) |
520 |
516 |
1 |
% |
Total Revenue |
8,313 |
6,044 |
38 |
% |
17,391 |
12,156 |
43 |
% |
Second Quarter 2021 Financial Highlights
Total revenues for the second quarter 2021 were $8.3 million, a
38% increase from $6.0 million in the second quarter 2020.
Excluding Sample Transport medium, revenues for the second quarter
2021 were $8.3 million, a 41% increase from $5.9 million in the
second quarter 2020.
Gross profit for the second quarter 2021 was $3.4 million,
compared to $3.5 million in the second quarter 2020. Gross margin
for the second quarter 2021 was 40.4% of revenue, compared to 57.4%
of revenue in the second quarter of 2020. Cost of sales in the
second quarter 2021 included a $0.7 million one-time reserve
related to excess Sample Transport medium inventory.
Operating expenses for the second quarter 2021 were $5.9 million
compared to $2.8 million in the second quarter 2020. The increase
was driven by increased headcount in research and development,
sales and marketing, and general and administrative functions to
support our new product development efforts, develop our commercial
presence and increase customer support, and build the
infrastructure necessary to support our growth strategy.
Net loss attributable to common stockholders for the second
quarter 2021 was $2.3 million, or $0.52 per share, compared to net
income attributable to common stockholders of $0.1 million, or
$0.02 per share, for the second quarter 2020.
Adjusted EBITDA for the second quarter 2021 was negative $1.5
million, compared to $1.2 million for the second quarter 2020.
As of June 30, 2021, the Company had $108.0 million in cash and
cash equivalents.
Conference Call and Webcast
Teknova will host a webcast and conference call today,
Wednesday, August 11, beginning at 4:30 p.m. ET. Participants may
access the live webcast on the Investor Relations section of the
Teknova website and at this link:
https://edge.media-server.com/mmc/p/avgvftny. The conference call
can be accessed by dialing 877-312-1451 for domestic callers and
470-495-9521 for international callers. The conference ID number is
2756899. A replay will be available for 30 days on the Investor
Relations section of the Teknova website.
About Teknova
Teknova is expediting clinical breakthroughs in the life
sciences by providing custom products and reagents for
bioprocessing, bioproduction, and molecular diagnostics. With a
focus on agility and customization, Teknova delivers research-grade
and GMP products including cell culture media and supplements,
protein and nucleic acid purification buffers, and molecular
biology reagents for a multitude of established and emerging
applications, including cell and gene therapy, mRNA therapeutics,
genomics, and synthetic biology. Teknova's proprietary processes
enable the manufacture and delivery of high quality, custom,
made-to-order products on short turnaround times and at scale
across all stages of development, including commercialization.
Non-GAAP Financial Measures
This press release contains financial measures that have not
been calculated in accordance with U.S. generally accepted
accounting principles (GAAP). Teknova uses the following non-GAAP
financial measures in assessing the performance of our business and
the effectiveness of our business strategies: (a) Adjusted EBITDA
and (b) Adjusted Free Cash Flow.
Teknova defines Adjusted EBITDA as net income (loss) adjusted
for interest expense, provision for income taxes, depreciation
expense, amortization of intangible assets and stock-based
compensation expenses. Adjusted EBITDA reflects further adjustments
to eliminate the impact of certain items, including certain
non-cash and other items that we do not consider representative of
our ongoing operating performance.
Teknova defines Adjusted Free Cash Flow as Adjusted EBITDA less
capital expenditures.
Teknova presents Adjusted EBITDA and Adjusted Free Cash Flow in
this press release because Teknova believes analysts, investors,
and other interested parties frequently use these measures to
evaluate companies in our industry and that they facilitate
comparisons on a consistent basis across reporting periods.
Further, Teknova believes they are helpful in highlighting trends
in our operating results because they exclude items that are not
indicative of our core operating performance.
Adjusted EBITDA and Adjusted Free Cash Flow have limitations as
analytical tools and you should not consider them in isolation or
as substitutes for analysis of our results as reported under GAAP.
Teknova may in the future incur expenses similar to the adjustments
in the presentation of Adjusted EBITDA. In particular, Teknova
expects to incur meaningful share-based compensation expense in the
future. Other limitations include the following, which Adjusted
EBITDA and Adjusted Free Cash Flow do not reflect:
- all expenditures or future requirements for capital
expenditures or contractual commitments;
- changes in our working capital needs;
- provision for income taxes, which may be a necessary element of
our costs and ability to operate;
- the costs of replacing the assets being depreciated, which will
often have to be replaced in the future;
- the non-cash component of employee compensation expense;
and
- the impact of earnings or charges resulting from matters we
consider not to be reflective, on a recurring basis, of our ongoing
operations.
In addition, Adjusted EBITDA and Adjusted Free Cash Flow may not
be comparable to similarly titled measures used by other companies
in our industry or across different industries.
A full reconciliation of these non-GAAP measures to the most
comparable GAAP measures is included at the end of this
release.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to our long-term growth strategy,
demand for our products, expansion of our production capacity and
commercial and R&D capabilities. The words, without limitation,
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. These forward-looking statements are based on management’s
current expectations and beliefs and are subject to uncertainties
and factors, all of which are difficult to predict and many of
which are beyond our control and could cause actual results to
differ materially and adversely from those described in the
forward-looking statements. These risks include, but are not
limited to, those related to our cash flows and revenue growth
rate; our supply chain, sourcing, manufacturing and warehousing;
inventory management; risks related to global economic and
marketplace uncertainties related to the impact of the COVID-19
pandemic; reliance on a limited number of customers for a high
percentage of our revenue; acquisitions of other companies and
other factors discussed in the “Risk Factors” section of our most
recent periodic reports filed with the Securities and Exchange
Commission (“SEC”), including in our final prospectus filed with
the SEC pursuant to Rule 424(b) under the Securities Act of 1933,
as amended, on June 25, 2021, all of which you may obtain for
free on the SEC’s website at www.sec.gov. Although we believe that
the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
ALPHA TEKNOVA,
INC.Condensed Balance
Sheets(unaudited)(in thousands,
except share and per share data)
|
|
As of June 30, 2021 |
|
|
As of December 31, 2020 |
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
108,022 |
|
|
|
$ |
3,315 |
|
Short-term investments |
|
|
— |
|
|
|
|
1,811 |
|
Accounts receivable, net |
|
|
4,058 |
|
|
|
|
4,623 |
|
Inventories |
|
|
3,880 |
|
|
|
|
3,582 |
|
Income taxes receivable |
|
|
1,638 |
|
|
|
|
1,417 |
|
Prepaid expenses and other current assets |
|
|
719 |
|
|
|
|
1,666 |
|
Total current
assets |
|
|
118,317 |
|
|
|
|
16,414 |
|
Property, plant and equipment,
net |
|
|
18,326 |
|
|
|
|
10,008 |
|
Goodwill |
|
|
16,613 |
|
|
|
|
16,613 |
|
Intangible assets, net |
|
|
19,278 |
|
|
|
|
19,852 |
|
Other non-current assets |
|
|
31 |
|
|
|
|
24 |
|
Total assets |
|
$ |
172,565 |
|
|
|
$ |
62,911 |
|
LIABILITIES,
CONVERTIBLE AND REDEEMABLE PREFERRED STOCK AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
2,640 |
|
|
|
$ |
1,635 |
|
Accrued liabilities |
|
|
3,301 |
|
|
|
|
2,327 |
|
Total current
liabilities |
|
|
5,941 |
|
|
|
|
3,962 |
|
Deferred tax liabilities |
|
|
5,242 |
|
|
|
|
5,990 |
|
Other accrued liabilities |
|
|
312 |
|
|
|
|
350 |
|
Long term debt |
|
|
11,782 |
|
|
|
|
— |
|
Deferred rent |
|
|
253 |
|
|
|
|
204 |
|
Total liabilities |
|
|
23,530 |
|
|
|
|
10,506 |
|
|
|
|
|
|
|
|
Convertible and redeemable
preferred stock |
|
|
— |
|
|
|
|
35,638 |
|
Stockholders’ equity: |
|
|
|
|
|
|
Common stock |
|
|
— |
|
|
|
|
— |
|
Additional paid-in capital |
|
|
149,675 |
|
|
|
|
14,495 |
|
(Accumulated deficit) retained earnings |
|
|
(640 |
) |
|
|
|
2,265 |
|
Accumulated other comprehensive income |
|
|
— |
|
|
|
|
7 |
|
Total stockholders’
equity |
|
|
149,035 |
|
|
|
|
16,767 |
|
Total liabilities,
convertible and redeemable preferred stock and stockholders’
equity |
|
$ |
172,565 |
|
|
|
$ |
62,911 |
|
ALPHA TEKNOVA,
INC.Condensed Statements of Operations and
Comprehensive Income
(Loss)(unaudited)(in thousands,
except share and per share data)
|
For the Three Months Ended June 30, |
|
For the Six Months Ended June
30, |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Revenue |
$ |
8,313 |
|
|
$ |
6,044 |
|
|
$ |
17,391 |
|
|
$ |
12,156 |
|
Cost of sales |
|
4,959 |
|
|
|
2,575 |
|
|
|
9,012 |
|
|
|
5,058 |
|
Gross profit |
|
3,354 |
|
|
|
3,469 |
|
|
|
8,379 |
|
|
|
7,098 |
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
|
851 |
|
|
|
341 |
|
|
|
1,548 |
|
|
|
667 |
|
Sales and marketing |
|
904 |
|
|
|
481 |
|
|
|
1,609 |
|
|
|
831 |
|
General and administrative |
|
3,838 |
|
|
|
1,656 |
|
|
|
8,002 |
|
|
|
3,310 |
|
Amortization of intangible assets |
|
287 |
|
|
|
287 |
|
|
|
574 |
|
|
|
574 |
|
Total operating
expenses |
|
5,880 |
|
|
|
2,765 |
|
|
|
11,733 |
|
|
|
5,382 |
|
(Loss) income from
operations |
|
(2,526 |
) |
|
|
704 |
|
|
|
(3,354 |
) |
|
|
1,716 |
|
Other income (expenses),
net |
|
|
|
|
|
|
|
Interest income (expense), net |
|
(304 |
) |
|
|
23 |
|
|
|
(296 |
) |
|
|
55 |
|
Other expense, net |
|
(3 |
) |
|
|
(4 |
) |
|
|
(2 |
) |
|
|
(25 |
) |
Total other income
(expenses), net |
|
(307 |
) |
|
|
19 |
|
|
|
(298 |
) |
|
|
30 |
|
(Loss) income before income
taxes |
|
(2,833 |
) |
|
|
723 |
|
|
|
(3,652 |
) |
|
|
1,746 |
|
(Benefit from) provision for income taxes |
|
(583 |
) |
|
|
211 |
|
|
|
(747 |
) |
|
|
286 |
|
Net (loss) income |
|
(2,250 |
) |
|
|
512 |
|
|
|
(2,905 |
) |
|
|
1,460 |
|
Less: undistributed income attributable to preferred
stockholders |
|
— |
|
|
|
(425 |
) |
|
|
— |
|
|
|
(1,211 |
) |
Net (loss) income attributable to common stockholders |
$ |
(2,250 |
) |
|
$ |
87 |
|
|
$ |
(2,905 |
) |
|
$ |
249 |
|
Net (loss) income per share
attributable to common stockholders |
|
|
|
|
|
|
|
Basic |
$ |
(0.52 |
) |
|
$ |
0.02 |
|
|
$ |
(0.73 |
) |
|
$ |
0.07 |
|
Diluted |
$ |
(0.52 |
) |
|
$ |
0.02 |
|
|
$ |
(0.73 |
) |
|
$ |
0.07 |
|
Weighted average shares used
in computing net (loss) income per share attributable to common
stockholders |
|
|
|
|
|
|
|
Basic |
4,328,222 |
|
|
3,599,232 |
|
|
3,965,741 |
|
|
3,599,232 |
|
Diluted |
4,328,222 |
|
|
3,636,724 |
|
|
3,965,741 |
|
|
3,636,724 |
|
ALPHA TEKNOVA,
INC.Reconciliation of Non-GAAP Measures to the
Most Comparable GAAP
Measures(unaudited)(in
thousands)
|
For the Three Months Ended June 30, |
|
For the Six Months Ended June
30, |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Net (loss) income – as
reported |
$ |
(2,250 |
) |
|
$ |
512 |
|
|
$ |
(2,905 |
) |
|
$ |
1,460 |
|
Add back: |
|
|
|
|
|
|
|
Interest expense (income),
net |
|
304 |
|
|
|
(23 |
) |
|
|
296 |
|
|
|
(55 |
) |
(Benefit from) provision for
income taxes |
|
(583 |
) |
|
|
211 |
|
|
|
(747 |
) |
|
|
286 |
|
Depreciation expense |
|
413 |
|
|
|
189 |
|
|
|
778 |
|
|
|
358 |
|
Amortization of intangible
assets |
|
287 |
|
|
|
287 |
|
|
|
574 |
|
|
|
574 |
|
EBITDA |
$ |
(1,829 |
) |
|
$ |
1,176 |
|
|
$ |
(2,004 |
) |
|
$ |
2,623 |
|
Other and one-time
expenses: |
|
|
|
|
|
|
|
Stock-based compensation
expense |
|
302 |
|
|
|
— |
|
|
|
485 |
|
|
|
— |
|
Adjusted
EBITDA |
$ |
(1,527 |
) |
|
$ |
1,176 |
|
|
$ |
(1,519 |
) |
|
$ |
2,623 |
|
Less: capital
expenditures |
|
(4,674 |
) |
|
|
(584 |
) |
|
|
(8,558 |
) |
|
|
(953 |
) |
Adjusted Free Cash
Flow |
$ |
(6,201 |
) |
|
$ |
592 |
|
|
$ |
(10,077 |
) |
|
$ |
1,670 |
|
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-216-1830
Sara Michelmore
MacDougall
smichelmore@macbiocom.com
+1 781-235-3060
Media Contact
Matthew Corcoran
MacDougall
mcorcoran@macbiocom.com
+1 617-866-7350
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2023 to Apr 2024